J&J Continues Atopic Dermatitis Effort With Numab Deal

 
• By Joseph Haas

Johnson & Johnson, after several prior failed R&D attempts in AD, will pay Numab $1.25bn to acquire a subsidiary and its Phase II-ready bispecific antibody for key unmet needs in the disease.

Hockey net (shots on goal)
Johnson & Johnson is lining up multiple shots at treating atopic dermatitis • Source: Shutterstock

More from Deals

More from Business